• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Perrigo Company plc

    5/7/25 5:23:16 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    S-8 1 d841944ds8.htm S-8 S-8

    As Filed with the Securities and Exchange Commission on May 7, 2025

    Registration Statement No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    PERRIGO COMPANY PLC

    (Exact name of registrant as specified in its charter)

     

     

     

    Ireland   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

      (IRS Employer
    Identification No.)

    The Sharp Building, Hogan Place

    Dublin 2, Ireland

    Telephone: +353 1 7094000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive office)

     

     

    PERRIGO COMPANY PLC 2019 LONG-TERM INCENTIVE PLAN

    (Full Title of the Plan)

     

     

    Charles M. Atkinson

    Executive Vice President, General Counsel and Company Secretary

    Perrigo Company plc

    515 Eastern Avenue

    Allegan, Michigan 49010

    Telephone: (269) 686-1941

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Alan J. Fishman

    Sullivan & Cromwell LLP

    125 Broad St

    New York, New York 10004

    (212) 558-4000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) relates to the registration of ordinary shares, nominal value €0.001 per share (the “Ordinary Shares”), of Perrigo Company plc (the “Company” or “Registrant”) to be offered under the Perrigo Company plc 2019 Long-Term Incentive Plan (the “2019 Plan”). The 2019 Plan was adopted as an amendment and restatement of the 2013 Long-Term Incentive Plan (the “2013 Plan”), which was adopted as an amendment and restatement of the 2008 Long-Term Incentive Plan (the “2008 Plan”), which was adopted as an amendment and restatement of the 2003 Long-Term Incentive Plan (the “2003 Plan”). The Company has earlier filed registration statements on Form S-8 (File No. 333-277416 and 333-270089 and 333-261074) relating to the 2019 Plan as well as a Form S-8 (File No. 333-192946) relating to the 2013 Plan, the 2008 Plan, the 2003 Plan (the “Earlier Registration Statements”). Except as modified or superseded herein, the contents of the Earlier Registration Statements are incorporated herein by reference. This Registration Statement is being filed by the Company pursuant to General Instruction E for Form S-8 to register the issuance of an additional 1,412,770 Ordinary Shares that have become available for delivery with respect to awards under the 2019 Plan pursuant to the share counting, share recycling and other terms and conditions of the 2019 Plan.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

    The following documents are filed or incorporated by reference as part of this Registration Statement.

     

    Exhibit
    Number

      

    Description of Exhibit

    4.1    Certificate of Incorporation of Perrigo Company plc (formerly known as Perrigo Company Limited) (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed December 19, 2013) (File No. 333-192946).
    4.2    Memorandum and Articles of Association of Perrigo Company plc, as amended and restated (incorporated by reference from Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on May 7, 2025) (File No. 001-36353).
    4.3    Perrigo Company plc 2019 Long-Term Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 30, 2019) (File No. 001-36353).
    4.4    Amendment No. 1 to Perrigo Company plc 2019 Long Term Incentive Plan (incorporated by reference from Exhibit  A to the Company’s Definitive Proxy Statement filed on March 24, 2022) (File No. 001-36353).
    4.5    Amendment No. 2 to the Perrigo Company plc 2019 Long-Term Incentive Plan, dated August  2, 2023 (incorporated by Reference from Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 7, 2023) (File No. 001-36353).
    4.6    Amendment No. 3 to the Perrigo Company plc 2019 Long-Term Incentive Plan, dated November  1, 2023 (incorporated by Reference from Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on November 7, 2023) (File No. 001-36353).
    5.1*    Opinion of A&L Goodbody

     

    1


    23.1*    Consent of Ernst & Young LLP, independent registered public accounting firm for Perrigo Company
    23.3*    Consent of A&L Goodbody (included in Exhibit 5.1)
    24.1*    Powers of Attorney (included as part of the signature page hereto)
    107*    Filing Fee Table

     

    *

    Filed herewith.

     

    2


    SIGNATURES AND POWER OF ATTORNEY

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on May 7, 2025.

     

    PERRIGO COMPANY PLC
    By:   /s/ Charles M. Atkinson
      Charles M. Atkinson
      Executive Vice President, General Counsel and Secretary

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Patrick Lockwood-Taylor, Eduardo Bezerra and Charles Atkinson, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated on May 7, 2025.

     

    Signature

      

    Title

    /s/ Patrick Lockwood-Taylor

    Patrick Lockwood-Taylor

      

    Chief Executive Officer and President

    (Principal Executive Officer) and Director

    /s/ Eduardo Bezerra

    Eduardo Bezerra

      

    Chief Financial Officer and Executive Vice President

    (Principal Accounting and Financial Officer)

    /s/ Orlando D. Ashford

    Orlando D. Ashford

       Director, Chairman of the Board

    /s/ Bradley A. Alford

    Bradley A. Alford

       Director

    /s/ Julia Brown

    Julia Brown

       Director

    /s/ Kevin Egan

    Kevin Egan

       Director

    /s/ Adriana Karaboutis

    Adriana Karaboutis

       Director

     

    3


    /s/ Jeffrey B. Kindler

    Jeffrey B. Kindler

       Director

    /s/ Albert A. Manzone

    Albert A. Manzone

       Director

    /s/ Donal O’Connor

    Donal O’Connor

       Director

    /s/ Geoffrey M. Parker

    Geoffrey M. Parker

       Director

    /s/ Jonas Samuelson

    Jonas Samuelson

       Director

     

    4

    Get the next $PRGO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    SEC Filings

    See more
    • Perrigo Company plc filed SEC Form 8-K: Regulation FD Disclosure

      8-K - PERRIGO Co plc (0001585364) (Filer)

      7/1/25 5:22:36 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Perrigo Company plc

      11-K - PERRIGO Co plc (0001585364) (Filer)

      6/26/25 2:33:44 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

      SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

      6/6/25 12:00:06 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Perrigo downgraded by Argus

      Argus downgraded Perrigo from Buy to Hold

      1/14/25 8:38:48 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Perrigo from Overweight to Neutral and set a new price target of $27.00 from $34.00 previously

      1/6/25 8:24:36 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Perrigo with a new price target

      Jefferies resumed coverage of Perrigo with a rating of Hold and set a new price target of $30.00 from $50.00 previously

      9/24/24 8:23:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and President of CSCI Khoury Roberto

      4 - PERRIGO Co plc (0001585364) (Issuer)

      7/10/25 11:41:30 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Alford Bradley A

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/17/25 2:22:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parker Geoffrey M.

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/17/25 2:18:53 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

      For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

      7/13/23 8:32:15 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance

      Company to Scale and Optimize Global Category-Led, Market Activation Growth Model Roberto Khoury, EVP & President Consumer Self-Care International (CSCI), Appointed to New Position of EVP & Chief Commercial Officer to Lead Global Market Activation Triona Schmelter, EVP & President Consumer Self-Care Americas (CSCA), to Leave Organization DUBLIN, July 1, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that it is scaling and optimizing its proven growth model—anchored in global Category Leadership and Market Activation—across the organization to enhance agility, accelerate innovation, and drive long-term sustainabl

      7/1/25 4:30:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Good Start® | Dr. Brown's™ Launches 30-Day "Gentle Baby Formula Giveaway Contest" with a Generous Donation to Baby2Baby

      Beginning July 1, 2025, a month-long giveaway contest will award 100 winners with two months' worth of Good Start® | Dr. Brown's™ Gentle Pro™ baby formula plus Dr. Brown's products (valued at $516.49) – and support families in need with a donation of formula to Baby2Baby that exceeds the total contest value GRAND RAPIDS, Mich., July 1, 2025 /PRNewswire/ -- Today, the makers of Good Start® | Dr. Brown's™ infant formula announced a nationwide giveaway contest to support families across the country. Beginning July 1st, the makers of Good Start® | Dr. Brown's™ will launch a month-long contest giving consumers the chance to win up to 500 bottles' worth of Good Start® | Dr. Brown's™ Gentle Pro™ fo

      7/1/25 9:02:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Global Operations and Supply Chain Leadership Transition

      Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

      6/4/25 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parker Geoffrey M. bought $94,850 worth of Ordinary Shares (3,500 units at $27.10), increasing direct ownership by 17% to 23,762 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/14/25 2:06:42 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Svend bought $27,900 worth of Ordinary Shares (1,000 units at $27.90), increasing direct ownership by 0.99% to 101,853 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/31/24 5:04:45 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison exercised 1,698 units of Ordinary Shares at a strike of $27.26, covered exercise/tax liability with 1,262 units of Ordinary Shares and bought $67,877 worth of Ordinary Shares (2,490 units at $27.26), increasing direct ownership by 24% to 15,372 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:58:50 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perrigo Announces Global Operations and Supply Chain Leadership Transition

      Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

      6/4/25 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer

      Expanded Scientific Office Unifies Scientific-Focused Teams, Facilitating Seamless Collaboration Across Product Portfolio Lennox Most Recently Led Regulatory, Medical Affairs, Safety and Quality Teams, Plus Drove Product Innovation, at Bayer Consumer Health Previous Chief Scientific Officer, Alison Ives, to Lead Newly Formed Disruptive Growth Team DUBLIN, Jan. 6, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the expansion of its Chief Scientific Office by uniting and integrating all global quality, pharmacovigilance, patient safety, regulatory affairs and innovation teams, enhancing organizational agility and s

      1/6/25 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

      Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General Counsel DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry. President and CEO Patrick Lockwood-Taylor commented, "I am very excited to welcome Charles to the Perrigo leadership team. His strat

      9/4/24 8:00:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Financials

    Live finance-specific insights

    See more
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Announces Quarterly Dividend

      DUBLIN, April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE:PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit

      4/30/25 10:23:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025

      DUBLIN, April 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2025 financial results on Wednesday, May 7th, 2025, and host a conference call beginning at 8:30 A.M. (EST).  The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 04449. A taped replay o

      4/23/25 4:47:00 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      10/31/24 11:55:03 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Perrigo Company plc

      SC 13G - PERRIGO Co plc (0001585364) (Subject)

      2/13/24 1:05:29 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Perrigo Company plc (Amendment)

      SC 13G/A - PERRIGO Co plc (0001585364) (Subject)

      1/24/24 2:27:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care